Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Sunshine Biopharma (SBFM) Return on Capital Employed (2016 - 2025)

Sunshine Biopharma (SBFM) has disclosed Return on Capital Employed for 10 consecutive years, with 0.26% as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Return on Capital Employed fell 6.0% year-over-year to 0.26%, compared with a TTM value of 0.26% through Sep 2025, down 6.0%, and an annual FY2024 reading of 0.26%, down 5.0% over the prior year.
  • Return on Capital Employed was 0.26% for Q3 2025 at Sunshine Biopharma, up from 0.26% in the prior quarter.
  • Across five years, Return on Capital Employed topped out at 0.1% in Q3 2022 and bottomed at 3.09% in Q1 2021.
  • Average Return on Capital Employed over 5 years is 0.75%, with a median of 0.26% recorded in 2025.
  • The sharpest move saw Return on Capital Employed crashed -390bps in 2021, then surged 278bps in 2022.
  • Year by year, Return on Capital Employed stood at 1.08% in 2021, then grew by 11bps to 0.96% in 2022, then skyrocketed by 77bps to 0.22% in 2023, then fell by -11bps to 0.24% in 2024, then fell by -7bps to 0.26% in 2025.
  • Business Quant data shows Return on Capital Employed for SBFM at 0.26% in Q3 2025, 0.26% in Q2 2025, and 0.24% in Q1 2025.